Eli Lilly CEO on Drug Pricing and Diabetes Treatment

The video discusses the evolving dynamics of drug pricing, highlighting the industry's efforts to curb price increases and improve patient affordability. It explores innovative pricing models, particularly in diabetes, and the role of pharmacy benefit managers (PBMs) in the drug supply chain. Lilly's strategic use of tax windfalls for investment and R&D is outlined, along with the competitive landscape for its drug Trulicity. The video also examines the FDA's impact on drug approval processes and market competition.

What role does patient convenience play in the success of diabetes medications like Trulicity?

What challenges does the FDA's faster drug approval process present to pharmaceutical companies?

How does competition in the pharmaceutical industry affect drug pricing?

In what ways can companies allocate their R&D budgets to address competitive pressures?